Allylic oxidation is of great importance in pharmaceutical manufacturing. Existing reaction schemes, however, involve toxic reagents, such as chromium, ruthenium, or selenium, and/or expensive catalysts, such as palladium or rhodium. These factors prevent the widespread use of allylic oxidation at industrial scale.
Scientists at The Scripps Research Institute (TSRI), in collaboration with pharmaceutical chemists at Bristol-Myers Squibb (BMS) and Asymchem Life Science, have developed a cheaper, more-efficient route to allylic oxidation. The new method employs an electric current instead of toxic or expensive materials to drive the reaction.
“One of the best reagents you can buy is sitting in your wall socket,” says Phil Baran, the Darlene Shiley Professor of Chemistry at TSRI.
Allylic oxidation is the oxidation of compounds with an allyl group (i.e., a carbon atom bonded to a...
Would you like to access the complete CEP News Update?
No problem. You just have to complete the following steps.
You have completed 0 of 2 steps.
-
Log in
You must be logged in to view this content. Log in now.
-
AIChE Membership
You must be an AIChE member to view this article. Join now.
Copyright Permissions
Would you like to reuse content from CEP Magazine? It’s easy to request permission to reuse content. Simply click here to connect instantly to licensing services, where you can choose from a list of options regarding how you would like to reuse the desired content and complete the transaction.
